Boston Scientific Co. (NYSE:BSX) Shares Acquired by Kathmere Capital Management LLC

Kathmere Capital Management LLC increased its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 29.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,510 shares of the medical equipment provider’s stock after purchasing an additional 1,034 shares during the period. Kathmere Capital Management LLC’s holdings in Boston Scientific were worth $403,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the stock. Thoroughbred Financial Services LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at about $203,000. J.W. Cole Advisors Inc. grew its position in Boston Scientific by 9.2% in the second quarter. J.W. Cole Advisors Inc. now owns 3,989 shares of the medical equipment provider’s stock valued at $307,000 after acquiring an additional 336 shares in the last quarter. Citizens Financial Group Inc. RI purchased a new stake in shares of Boston Scientific during the second quarter valued at approximately $274,000. Edgestream Partners L.P. boosted its stake in shares of Boston Scientific by 64.7% in the second quarter. Edgestream Partners L.P. now owns 8,796 shares of the medical equipment provider’s stock valued at $677,000 after purchasing an additional 3,455 shares during the period. Finally, Axxcess Wealth Management LLC boosted its stake in shares of Boston Scientific by 3.7% in the second quarter. Axxcess Wealth Management LLC now owns 10,452 shares of the medical equipment provider’s stock valued at $805,000 after purchasing an additional 377 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

BSX stock opened at $98.15 on Friday. Boston Scientific Co. has a 1 year low of $59.85 and a 1 year high of $98.31. The stock has a market capitalization of $144.65 billion, a price-to-earnings ratio of 81.11, a PEG ratio of 2.48 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The stock’s fifty day moving average is $90.57 and its two-hundred day moving average is $84.23.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The firm had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same period last year, the firm posted $0.50 EPS. Boston Scientific’s quarterly revenue was up 19.3% compared to the same quarter last year. On average, research analysts predict that Boston Scientific Co. will post 2.46 EPS for the current year.

Analysts Set New Price Targets

BSX has been the topic of a number of recent analyst reports. TD Cowen boosted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research note on Friday, January 10th. Bank of America raised their price objective on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Evercore ISI upped their target price on Boston Scientific from $82.00 to $90.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, Truist Financial raised their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.26.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now owns 39,398 shares of the company’s stock, valued at $3,610,038.74. The trade was a 11.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares of the company’s stock, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 29,989 shares of company stock worth $2,702,261. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.